New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation

Bibliography

• Badesch DB, Champion HC, Sanchez MA, Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-66
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA, Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S78-84
   PubMed Web of Science ®Google Scholar
• Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-38
   PubMed Web of Science ®Google Scholar
• van Wolferen SA, Marcus JT, Boonstra A, Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:1250-7
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Mouthon L, Barbera JA, Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:S10-19
   PubMed Web of Science ®Google Scholar
• Morrell NW, Adnot S, Archer SL, Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S20-31
   PubMed Web of Science ®Google Scholar
• Machado RD, Eickelberg O, Elliott CG, Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S32-42
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Barst RJ, Benza RL, Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S108-117
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-95
   PubMed Web of Science ®Google Scholar
• Michelakis ED, McMurtry MS, Wu XC, Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002;105:244-50
   PubMed Web of Science ®Google Scholar
• Yuan JX, Aldinger AM, Juhaszova M, Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;98:1400-6
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Wu X, Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830-40
   PubMed Web of Science ®Google Scholar
• Piao L, Fang YH, Cadete VJ, The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med 2010;88:47-60
   PubMed Web of Science ®Google Scholar
• Zhang TT, Cui B, Dai DZ. Downregulation of Kv4.2 and Kv4.3 channel gene expression in right ventricular hypertrophy induced by monocrotaline in rat. Acta Pharmacol Sin 2004;25:226-30
   PubMed Web of Science ®Google Scholar
• Bonnet S, Michelakis ED, Porter CJ, An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113:2630-41
   PubMed Web of Science ®Google Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51
   PubMed Web of Science ®Google Scholar
• Moudgil R, Michelakis ED, Archer SL. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 2006;13:615-32
   PubMed Web of Science ®Google Scholar
• Guignabert C, Tu L, Izikki M, Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 2009;23:4135-47
   PubMed Web of Science ®Google Scholar
• Nagendran J, Gurtu V, Fu DZ, A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg 2008;136:168-78
   PubMed Web of Science ®Google Scholar
• de Frutos S, Spangler R, Alo D, NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation. J Biol Chem 2007;282:15081-9
   PubMed Web of Science ®Google Scholar
• Bonnet S, Rochefort G, Sutendra G, The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007;104:11418-23
   PubMed Web of Science ®Google Scholar
• Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 2003;92:725-31
   PubMed Web of Science ®Google Scholar
• Rossow CF, Minami E, Chase EG, NFATc3-induced reductions in voltage-gated K+ currents after myocardial infarction. Circ Res 2004;94:1340-50
   Google Scholar
• Wang C, Li JF, Zhao L, Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. Respir Res 2009;10:123
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Archer SL, Altieri DC, Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91
   PubMed Web of Science ®Google Scholar
• Blanc-Brude OP, Yu J, Simosa H, Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 2002;8:987-94
   PubMed Web of Science ®Google Scholar
• Wang GJ, Sui XX, Simosa HF, Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol 2005;25:2081-7
   PubMed Web of Science ®Google Scholar
• Plescia J, Salz W, Xia F, Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68
   PubMed Web of Science ®Google Scholar
• Hansmann G, Wagner RA, Schellong S, Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007;115:1275-84
   PubMed Web of Science ®Google Scholar
• Guignabert C, Alvira CM, Alastalo TP, Tie2-mediated loss of peroxisome proliferator-activated receptor-{gamma} in mice causes PDGF-receptor {beta}-dependant pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009;23:4135-47
   Google Scholar
• Crossno JT Jr, Garat CV, Reusch JE, Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007;292:L885-897
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Hoshikawa Y, Ameshima S, Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 2005;43:283-8
   PubMedGoogle Scholar
• Law RE, Goetze S, Xi XP, Expression and function of PPAR-gamma in rat and human vascular smooth muscle cells. Circulation 2000;101:1311-8
   PubMed Web of Science ®Google Scholar
• Falcetti E, Flavell DM, Staels B, IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. Biochem Biophys Res Commun 2007;360:821-7
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Lipscombe LL, Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population-based cohort study. BMJ 2009;339:b2942
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Stasch JP, Pullamsetti SS, Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-91
   PubMed Web of Science ®Google Scholar
• de Frutos S, Nitta CH, Caldwell E, Regulation of soluble guanylyl cyclase-alpha1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR. Am J Physiol Lung Cell Mol Physiol 2009;297:L475-486
   PubMed Web of Science ®Google Scholar
• Li D, Zhou N, Johns RA. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol 1999;277:L841-847
   PubMed Web of Science ®Google Scholar
• Vermeersch P, Buys E, Pokreisz P, Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation 2007;116:936-43
   PubMed Web of Science ®Google Scholar
• Dumitrascu R, Weissmann N, Ghofrani HA, Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-95
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Pacher P, Schmidt PM, NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-68
   PubMed Web of Science ®Google Scholar
• Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005;289:L798-806
   PubMed Web of Science ®Google Scholar
• Frey R, Muck W, Unger S, Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 2008;48:1400-10
   PubMed Web of Science ®Google Scholar
• Grimminger F, Weimann G, Frey R, First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-92
   PubMed Web of Science ®Google Scholar
• Yu Y, Sweeney M, Zhang S, PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 2003;284:C316-330
   PubMed Web of Science ®Google Scholar
• Perros F, Montani D, Dorfmuller P, Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-8
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
   PubMed Web of Science ®Google Scholar
• Smyth MJ. Imatinib mesylate–uncovering a fast track to adaptive immunity. N Engl J Med 2006;354:2282-4
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3
   PubMed Web of Science ®Google Scholar
• Patterson KC, Weissmann A, Ahmadi T, Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152-3
   PubMed Web of Science ®Google Scholar
• Souza R, Sitbon O, Parent F, Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM, Imatinib in patients with severe pulmonary artery hypertension (PAH) refractory to standard therapy [abstract]. Am J Respir Crit Care Med 2009;179:A1044
   Google Scholar
• Kerkela R, Grazette L, Yacobi R, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16
   PubMed Web of Science ®Google Scholar
• Klein M, Schermuly RT, Ellinghaus P, Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118:2081-90
   PubMed Web of Science ®Google Scholar
• Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008;33:278-91
   PubMedGoogle Scholar
• Gomberg-Maitland M. Tyrosine kinase inhibitors and antiangiogenesis agents in PAH: sorafenib as a therapy for PAH: results of a phase I drug dosing safety trial [abstract 388]. American Thoracic Society, Toronto; May 2008
   Google Scholar
• Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21-34
   PubMed Web of Science ®Google Scholar
• Fagan KA, Oka M, Bauer NR, Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656-664
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Fagan KA, Gebb SA, Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-9
   PubMed Web of Science ®Google Scholar
• Wang Z, Jin N, Ganguli S, Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am J Respir Cell Mol Biol 2001;25:628-35
   PubMed Web of Science ®Google Scholar
• Guilluy C, Eddahibi S, Agard C, RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 2009;179:1151-8
   PubMed Web of Science ®Google Scholar
• Abe K, Shimokawa H, Morikawa K, Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385-93
   PubMed Web of Science ®Google Scholar
• Ishikura K, Yamada N, Ito M, Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006;70:174-8
   PubMed Web of Science ®Google Scholar
• McNamara PJ, Murthy P, Kantores C, Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am J Physiol Lung Cell Mol Physiol 2008;294:L205-213
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Matoba T, Ito A, Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-2
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul JL, Berry GJ, Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403-8
   PubMed Web of Science ®Google Scholar
• Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-71
   PubMed Web of Science ®Google Scholar
• Dichtl W, Dulak J, Frick M, HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:58-63
   PubMed Web of Science ®Google Scholar
• Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL, Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5
   PubMed Web of Science ®Google Scholar
• Xing XQ, Gan Y, Wu SJ, Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. Med Hypotheses 2007;68:1108-13
   PubMed Web of Science ®Google Scholar
• Girgis RE, Li D, Zhan X, Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003;285:H938-945
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee DS, Kim EK, Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-676
   PubMed Web of Science ®Google Scholar
• Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 2008;294:H801-809
   PubMed Web of Science ®Google Scholar
• Satoh K, Fukumoto Y, Nakano M, Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009;81:226-34
   PubMed Web of Science ®Google Scholar
• Carlin CM, Peacock AJ, Welsh DJ. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 2007;37:447-56
   PubMed Web of Science ®Google Scholar
• Brown WV. Hydroxymethylglutaryl coenzyme a reductase inhibition: fluvastatin, a clinical investigators' update. Introduction. Am J Cardiol 1994;73:1D-2D
   PubMed Web of Science ®Google Scholar
• Murata T, Kinoshita K, Hori M, Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2005;25:2335-42
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Michelakis ED, Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007;293:L933-940
   PubMed Web of Science ®Google Scholar
• Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005;127:1446-52
   PubMed Web of Science ®Google Scholar
• Lee TM, Chen CC, Shen HN, Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009;116:497-505
   PubMed Web of Science ®Google Scholar
• Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970;169:1217-8
   PubMed Web of Science ®Google Scholar
• Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001;49:27-37
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46
   PubMed Web of Science ®Google Scholar
• Vuckovic A, Rondelet B, Brion JP, Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets. Pediatr Res 2009;66:395-9
   PubMed Web of Science ®Google Scholar
• Hamidi SA, Szema AM, Lyubsky S, Clues to VIP function from knockout mice. Ann NY Acad Sci 2006;1070:5-9
   PubMed Web of Science ®Google Scholar
• Said SI, Hamidi SA, Dickman KG, Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007;115:1260-8
   PubMed Web of Science ®Google Scholar
• Hamidi SA, Szema A, Said SI. A single pathogenetic mechanism for vascular remodeling and inflammation in PAH [abstract 275]. European Respiratory Society Annual Congress; 2008
   Google Scholar
• Haydar S, Sarti JF, Grisoni ER. Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension. J Pediatr Surg 2007;42:758-64
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Baezner C, Baumgartner RA, Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32:1289-94
   PubMed Web of Science ®Google Scholar
• Wernig K, Griesbacher M, Andreae F, Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release 2008;130:192-8
   PubMed Web of Science ®Google Scholar
• Quinn DA, Dahlberg CG, Bonventre JP, The role of Na+/H+ exchange and growth factors in pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol 1996;14:139-45
   PubMed Web of Science ®Google Scholar
• Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000;105:21-34
   PubMed Web of Science ®Google Scholar
• Lepetit H, Eddahibi S, Fadel E, Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:834-42
   PubMed Web of Science ®Google Scholar
• Todorovich-Hunter L, Dodo H, Ye C, Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis 1992;146:213-23
   PubMed Web of Science ®Google Scholar
• Cowan KN, Heilbut A, Humpl T, Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000;6:698-702
   PubMed Web of Science ®Google Scholar
• Vieillard-Baron A, Frisdal E, Eddahibi S, Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 2000;87:418-25
   PubMed Web of Science ®Google Scholar
• Zaidi SH, You XM, Ciura S, Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 2002;105:516-21
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Humbert M, Fadel E, Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-50
   PubMed Web of Science ®Google Scholar
• Guignabert C, Raffestin B, Benferhat R, Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:2812-9
   PubMed Web of Science ®Google Scholar
• MacLean MR, Herve P, Eddahibi S, 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-8
   PubMed Web of Science ®Google Scholar
• Rondelet B, Van Beneden R, Kerbaul F, Expression of the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 2003;22:408-12
   PubMed Web of Science ®Google Scholar
• Guignabert C, Izikki M, Tu LI, Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006;98:1323-30
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Hanoun N, Lanfumey L, Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000;105:1555-62
   PubMed Web of Science ®Google Scholar
• Keegan A, Morecroft I, Smillie D, Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001;89:1231-9
   PubMed Web of Science ®Google Scholar
• Marcos E, Adnot S, Pham MH, Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003;168:487-93
   PubMed Web of Science ®Google Scholar
• Hironaka E, Hongo M, Sakai A, Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003;60:692-9
   PubMed Web of Science ®Google Scholar
• Kawut SM, Horn EM, Berekashvili KK, Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006;19:370-4
   PubMed Web of Science ®Google Scholar
• Domenighetti G, Leuenberger P, Feihl F. Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension. Monaldi Arch Chest Dis 1997;52:429-33
   PubMedGoogle Scholar
• Morecroft I, Heeley RP, Prentice HM, 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 1999;128:730-4
   PubMed Web of Science ®Google Scholar
• Vizza CD, Letizia C, Sciomer S, Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul Pept 2005;124:187-93
   PubMed Web of Science ®Google Scholar
• Kakishita M, Nishikimi T, Okano Y, Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 1999;96:33-9
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 2000;84:653-8
   PubMed Web of Science ®Google Scholar
• Nagaya N, Okumura H, Uematsu M, Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 2003;285:H2125-2131
   PubMed Web of Science ®Google Scholar
• Qi JG, Ding YG, Tang CS, Chronic administration of adrenomedullin attenuates hypoxic pulmonary vascular structural remodeling and inhibits proadrenomedullin N-terminal 20-peptide production in rats. Peptides 2007;28:910-9
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M, Takamisawa I, Miyata K, Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats. Mol Ther 2009;17:1180-6
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kyotani S, Uematsu M, Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004;109:351-6
   PubMed Web of Science ®Google Scholar
• Smadja DM, Gaussem P, Mauge L, Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-81
   PubMed Web of Science ®Google Scholar
• Toshner M, Voswinckel R, Southwood M, Evidence for dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009;180:780-7
   PubMed Web of Science ®Google Scholar
• Fadini GP, Schiavon M, Rea F, Depletion of endothelial progenitor cells may link pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2007;176:724-5
   PubMed Web of Science ®Google Scholar
• Junhui Z, Xingxiang W, Guosheng F, Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med 2008;102:1073-9
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kangawa K, Kanda M, Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003;108:889-95
   PubMed Web of Science ®Google Scholar
• Takemiya K, Kai H, Yasukawa H, Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 2009;105:403-17
   Google Scholar
• Raoul W, Wagner-Ballon O, Saber G, Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice. Respir Res 2007;8:8
   PubMed Web of Science ®Google Scholar
• Takahashi M, Nakamura T, Toba T, Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng 2004;10:771-9
   PubMedGoogle Scholar
• Zhao YD, Courtman DW, Deng Y, Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-50
   PubMed Web of Science ®Google Scholar
• Umar S, de Visser YP, Steendijk P, Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009;297:H1606-1616
   PubMed Web of Science ®Google Scholar
• Campbell AI, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1999;21:567-75
   PubMed Web of Science ®Google Scholar
• Campbell AI, Zhao Y, Sandhu R, Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001;104:2242-8
   PubMed Web of Science ®Google Scholar
• Zhao YD, Campbell AI, Robb M, Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 2003;92:984-91
   PubMed Web of Science ®Google Scholar
• Wang XX, Zhang FR, Shang YP, Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007;49:1566-71
   PubMed Web of Science ®Google Scholar
• Grigg A, Buchanan M, Whitford H. Late-onset pulmonary arterial hypertension in association with graft-versus-host disease after allogeneic stem-cell transplantation. Am J Hematol 2005;80:38-42
   PubMed Web of Science ®Google Scholar
• Steward CG, Pellier I, Mahajan A, Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol 2004;124:63-71
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Perros F, Balabanian K, Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63
   PubMed Web of Science ®Google Scholar
• Lee SD, Shroyer KR, Markham NE, Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-34
   PubMed Web of Science ®Google Scholar
• Nicolls MR, Taraseviciene-Stewart L, Rai PR, Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005;26:1110-8
   PubMed Web of Science ®Google Scholar
• Cool CD, Stewart JS, Werahera P, Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-9
   PubMed Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Souza R, Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007;29:462-8
   PubMed Web of Science ®Google Scholar
• Tuder RM, Groves B, Badesch DB, Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85
   PubMed Web of Science ®Google Scholar
• Isern RA, Yaneva M, Weiner E, Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 1992;93:307-12
   PubMed Web of Science ®Google Scholar
• Tamby MC, Chanseaud Y, Humbert M, Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005;60:765-72
   PubMed Web of Science ®Google Scholar
• Tamby MC, Humbert M, Guilpain P, Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006;28:799-807
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Brenot F, Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31
   PubMed Web of Science ®Google Scholar
• Sanchez O, Marcos E, Perros F, Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007;176:1041-7
   PubMed Web of Science ®Google Scholar
• Balabanian K, Foussat A, Dorfmuller P, CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1419-25
   PubMed Web of Science ®Google Scholar
• Fartoukh M, Emilie D, Le Gall C, Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 1998;114:50S-1S
   PubMed Web of Science ®Google Scholar
• Quarck R, Nawrot T, Meyns B, C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:1211-8
   PubMed Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Souza R, Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007;29:937-43
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tuder RM, Bridges J, Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994;11:664-75
   PubMed Web of Science ®Google Scholar
• Savale L, Tu L, Rideau D, Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009;10:6
   PubMed Web of Science ®Google Scholar
• Wang GS, Qian GS, Mao BL, Changes of interleukin-6 and Janus kinases in rats with hypoxic pulmonary hypertension. Zhonghua Jie He He Hu Xi Za Zhi 2003;26:664-7
   PubMedGoogle Scholar
• Golembeski SM, West J, Tada Y, Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 2005;128:572S-3S
   PubMed Web of Science ®Google Scholar
• Steiner MK, Syrkina OL, Kolliputi N, Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-44, 228p following 244
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Yonemitsu Y, Kataoka C, Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002;283:H2021-2028
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul JL, Berry GJ, 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001;163:498-502
   PubMed Web of Science ®Google Scholar
• Zhou H, Liu H, Porvasnik SL, Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab Invest 2006;86:62-71
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Pullamsetti SS, Kwapiszewska G, Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 2007;115:2331-9
   PubMed Web of Science ®Google Scholar
• Wei L, Liu T, Liu B, Effect of triptolide on the development of monocrotaline-induced pulmonary hypertension in pneumonectomized rat. Sichuan Da Xue Xue Bao Yi Xue Ban 2007;38:806-9
   PubMedGoogle Scholar
• Tofovic SP, Salah EM, Mady HH, Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2005;46:430-7
   PubMed Web of Science ®Google Scholar
• Gui Y, Zheng XL. 2-methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells. Hypertension 2006;47:271-80
   PubMed Web of Science ®Google Scholar
• Ogawa A, Nakamura K, Matsubara H, Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005;112:1806-12
   PubMed Web of Science ®Google Scholar
• Csiszar A, Labinskyy N, Olson S, Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009;54:668-75
   PubMed Web of Science ®Google Scholar
• Sanchez O, Sitbon O, Jais X, Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-9
   PubMed Web of Science ®Google Scholar
• Bellotto F, Chiavacci P, Laveder F, Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax 1999;54:372-4
   PubMed Web of Science ®Google Scholar
• Sanchez O, Humbert M, Sitbon O, Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999;54:273-7
   PubMed Web of Science ®Google Scholar
• Sun CK, Lee FY, Sheu JJ, Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats. J Pharmacol Exp Ther 2009;330:718-26
   PubMed Web of Science ®Google Scholar
• Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007;50:195-200
   PubMed Web of Science ®Google Scholar
• Jiang BH, Tawara S, Abe K, Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007;49:85-9
   PubMed Web of Science ®Google Scholar
• Satoh M, Satoh A. 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. J Pharm Pharm Sci 2008;11:118s-30s
   Web of Science ®Google Scholar
• Zhao L, Sebkhi A, Ali O, Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009;34:948-57
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Ziegelhoeffer T, Heil M, Circulating vascular progenitor cells do not contribute to compensatory lung growth. Circ Res 2003;93:372-9
   PubMed Web of Science ®Google Scholar
• Oka M, Homma N, Taraseviciene-Stewart L, Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-9
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Gebb SA, Karoor V, Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 2006;100:996-1002
   PubMed Web of Science ®Google Scholar
• Liu B, Wang XQ, Yu L, Simvastatin restores down-regulated GATA-6 expression in pulmonary hypertensive rats. Exp Lung Res 2009;35:411-26
   PubMed Web of Science ®Google Scholar
• Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 2008;1144:148-53
   PubMed Web of Science ®Google Scholar